Abstract: Provided is a method of purifying a terpenoid amino alcohol derivative, including providing a crude terpenoid amino alcohol derivative; performing an acid/base crystallization process of the crude terpenoid amino alcohol derivative to obtain an organic salt; and reacting the organic salt with NaOH and toluene to obtain a purified terpenoid amino alcohol derivative. Also provided is a method of preparing p-mentha-2,8-diene-1-ol from the purified terpenoid amino alcohol derivative.

Abstract: Provided is a method of purifying a terpenoid amino alcohol derivative, including providing a crude terpenoid amino alcohol derivative; performing an acid/base crystallization process of the crude terpenoid amino alcohol derivative to obtain an organic salt; and reacting the organic salt with NaOH and toluene to obtain a purified terpenoid amino alcohol derivative. Also provided is a method of preparing p-mentha-2,8-diene-1-ol from the purified terpenoid amino alcohol derivative.

Abstract: Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

Abstract: Provided is a compound represented by Formula (VI) for preparing lisdexamphetamine or a salt thereof. Also provided is a method for preparing lisdexamfetamine or a salt thereof including performing reduction and debenzylation of the compound represented by Formula (VI) by hydrogenation.

Abstract: Provided is a method for preparing synthetic cannabidiol, including hydrolysis-decarboxylation of a compound represented by formula (II) in a solvent-free state under atmospheric pressure. The method further includes preparation of the compound represented by formula (II). The method provides a safe, economical, environmentally friendly and scalable method for synthetic preparation of cannabidiol.

Abstract: Provided is a method for preparing a tropane derivative, maraviroc, including reacting a compound of formula (II) with a compound of formula (I), wherein the compound of formula (II) is prepared by the steps of acetylation of a compound of formula (III), activation and substitution of a compound of formula (IV) by a chlorination agent, cyclization of a compound of formula (V), and debenzylation of a compound of formula (VI) by hydrogenation. Hence, the present disclosure provides a method for preparing maraviroc with good yield and simple operation.

Abstract: Provided is a method for preparing pimavanserin including reacting an intermediate compound represented by Formula (II) with N-(4-fluorobenzyl)-1-methylpiperidin-4-amine or a salt thereof, or reacting an intermediate compound represented by Formula (IV) with 4-isobutoxybenzylamine or a salt thereof, wherein L represents a heteroaryl group, —OR1 or halogen, and wherein R1 represents C1 to C10 alkyl or aryl. The present disclosure provides the method for preparing pimavanserin without the use of isocyanate intermediate.

Abstract: A method of producing optically pure N-substituted-3-methoxy propionic acid is provided, which includes the steps of: reacting N-substituted-3-methoxy propionic acid represented by formula (III): with a chiral amine in a solvent to obtain a diastereomeric salt represented by formula (IV): subjecting the diastereomeric salt to a sequential washing process to obtain the optically pure N-substituted-3-methoxy propionic acid represented by one of formulae (Ia) and (Ib): wherein R1 is selected from the group consisting of C1-5 alkyl, C1-6 alkoxy and C6-10 aryloxy group, and R2 is selected from the group consisting of C2-5 alkyl, C6-8 cycloalkyl and C6-10 aryl.

Abstract: A method for preparing acetazolamide sodium powder for injection is provided. The method includes steps of providing an acetazolamide sodium solution; and aseptically spray drying the acetazolamide sodium solution to obtain the acetazolamide sodium powder.

Abstract: The present invention provides a process for preparing duloxetine hydrochloride with higher yield and lower cost.

Abstract: A method for preparing tobramycin sulfate powder for injection is provided. The method includes steps of providing a sterile tobramycin sulfate solution; and aseptically spray drying the tobramycin sulfate solution to obtain the tobramycin sulfate powder.

Abstract: The present invention provides a simple, safe and more efficient process for preparing metal salts of valproic acid. The process includes steps of: (i) mixing valproic acid and a metal hydroxide (either dry solid or aqueous solution) in a drier to form a reaction mixture; and (ii) removing water, which is produced during the step of mixing the valproic acid and the metal hydroxide, from the reaction mixture to obtain the desired metal salts of valproic acid.

Abstract: The present invention provides a process for preparing duloxetine hydrochloride with higher yield and lower cost.

Abstract: The present invention provides a process for preparing a N-methyl-N-hydroxyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine compound. The present invention also provides a process for preparing (S)-(+)-N-methyl-3-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine with higher yield and low treatment cost, which includes the preparation of the N-methyl-N-hydroxyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine compound.

Abstract: The present invention provides (S)-methylhydroxylaminopropanol compound as an intermediate in preparation of (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine. The present invention also provides a process for preparing (S)-(+)-N-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine with higher yield and lower cost by using the (S)-methylhydroxylaminopropanol compound as an intermediate.

Abstract: The present invention provides an (S)-methylhydroxylaminopropanol compound and the (S)-methylhydroxylaminopropanol compound of the present invention is used as an intermediate for preparation of (S)-(?)-3-methylamino-1-(2-thienyl)propan-1-ol, which is an intermediate for preparation of (S)-(+)-N-methyl-3-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate. The present invention also provides a process for preparing (S)-(+3-methylamino-1-(2-thienyl)propan-1-ol with higher yield and lower cost, wherein the (S)-methylhydroxylaminopropanol compound is used as an intermediate.

Abstract: The present invention provides an efficient method for preparing atomoxetine in high yield. (R)-methylhydroxylaminopropanol compound of formula (II) in the present invention is used as an intermediate without the need for resolution processes.

Abstract: The present invention provides a novel method for preparing chiral Baclofen with higher yield, higher e.e. value, and lower cost via chiral Michael addition.

Abstract: The present invention provides an (S)-methylhydroxylaminopropanol compound and the (S)-methylhydroxylaminopropanol compound of the present invention is used as an intermediate for preparation of (S)-(?)-3-methylamino-1-(2-thienyl)propan-1-ol, which is an intermediate for preparation of (S)-(+)-N-methyl-3-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate. The present invention also provides a process for preparing (S)-(+3-methylamino-1-(2-thienyl)propan-1-ol with higher yield and lower cost, wherein the (S)-methylhydroxylaminopropanol compound is used as an intermediate.

Abstract: The present invention provides an (S)-methylhydroxylaminopropanol derivative and the (S)-methylhydroxylaminopropanol derivative of the present invention is used as an intermediate for preparation of (S)-(?)-3-methylamino-1-(2-thienyl)propan-1-ol, which is an intermediate for preparation of (S)-(+)-N-methyl-3-methyl-3-(1-naphthyloxy)-3-(2-thienyl)propylamine oxalate. The present invention also provides a process for preparing (S)-(?)-3-methylamino-1-(2-thienyl)propan-1-ol with higher yield and lower cost, wherein the (S)-methylhydroxylaminopropanol derivative is used as an intermediate.